Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal, Prospective, Multicenter, 2:1 Randomized, Double Blind, Controlled, Study Comparing the THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension (The THRIVE Study)

NCT06559891 is registered in ClinicalTrials.gov with SoniVie Inc. as lead sponsor.

NCT NCT06559891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06559891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal, Prospective, Multicenter, 2:1 Randomized, Double Blind, Controlled, Study Comparing the THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension (The THRIVE Study)
Lead sponsor
SoniVie Inc.
Phase
Not applicable
Overall status
Recruiting
Start date
October 3, 2024
Completion date
August 15, 2028
Enrollment
261 (estimated)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension